Lonza announces head of Lonza Bioscience

Takes over the position next month

As of 1 June, Lukas Utiger, currently chief operating officer of Lonza Life Science Ingredients, will become COO of Lonza Bioscience, located in Walkersville, Maryland, US. He will replace Anja Fiedler who has resigned for personal health reasons.

Stefan Borgas, chief executive, will take over the leadership of the Life Science Ingredients business in addition to his current responsibilities for the next few months until a successor has been recruited.

You may also like

Manufacturing

Lonza launches Design2Optimise platform to streamline API development

The Design2Optimise platform contributes to improved efficiencies and timelines to clinical trials of small molecule APIs
Drug Delivery

Lonza and Ethris team up to develop mRNA vaccines for respiratory diseases

The two hope to produce a temperature-stable mRNA vaccine for influenza, which may promote mucosal immunity through its nasal delivery system
Manufacturing

Lonza's Oregon site adds bottling and labelling capabilities in strategic upgrade

The company is now able to offer tablet and capsule bottling equipment, which can provide medicines to early-phase clinical trials
Manufacturing

Leucid Bio chooses Lonza automated personalised CAR T-Cells platform

Leucid will utilise Lonza as its preferred manufacturer, aiming to deliver high quality cell therapies quickly and cost-effectively to patients in a decentralised manufacturing model
Pharmaceutical

Lonza expands solid form services for small molecule drugs

Lonza has announced the expansion of its solid form selection services based at its Bend, OR (US) site
Finance

Lonza reports strong 2020 performance

Lonza results mainly reflect Pharma Biotech & Nutrition (LPBN) performance, as Specialty Ingredients (LSI) is reported as a discontinued operation
Manufacturing

Lonza expands conjugation facility with two additional manufacturing suites

The expansion of bioconjugation capabilities will provide development and manufacturing capacity for pre-clinical to commercial supply
Subscribe now